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Abstract
Cytotoxicity of drugs can be a cause of cardiorespiratory disorders connected with chemo-
therapy. Doxorubicin is an antibiotic from the group of anthracyclines effective in antineoplas-
tic therapy of solid and hematopoetic tumors. The most common cause of therapy ceasing is its
cardiotoxicity. However, a lung injury connected with its cytotoxic activity to pulmonary
endothelium (capillary leak syndrome) can be an equally serious complication. In the case
presented, rapid, multi-profile diagnostics with the use of impedance cardiography, a modern
noninvasive tool of hemodynamic monitoring, led to the recognition and effective treatment of
a rare clinical syndrome. (Cardiol J 2010; 17, 1: 88–91)
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Introduction
Noncardiogenic pulmonary edema (NCPE) is
a rare and barely known clinical syndrome caused
by toxic injury of the lungs connected with chemo-
therapy. It is characterized by breathing disorders,
chest discomfort, hypoxemia and a gradual deteri-
oration of a patient’s general condition, with a lack
of heart failure evidence [1, 2]. Capillary leak syn-
drome (CLS) can be one of the causes of cardiores-
piratory disorders connected with pharmacothera-
py and it is connected with pulmonary endothelial
damage and leakage of pulmonary capillary vessels [1].
Doxorubicin (adriamicin, adriblastin) is a cytostat-
ic antibiotic from the group of anthracyclines, fre-
quently used in the treatment of solid and hemato-
poetic tumors. Anthracyclines are very effective.
But their use is limited due to serious adverse
effects, especially the most frequent: cardiotoxici-
ty [3]. The case we present exemplifies another
severe complication of doxorubicin therapy con-
nected with its pulmotoxicity and is a significant
clinical problem requiring rapid and specific treat-
ment.
Case report
A 71 year-old male suffering from myeloma
multiplex Ig A (stage III) was admitted to the
Department of Internal Diseases and Hematology
of Military Medical Institute for the second cycle
of chemotherapy (VAD, vincristine, doxorubicin,
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dexamethasone). On admission, the patient was in
a rather good general state, afebrile, complaining
about general weakening, decreased exercise to-
lerance, symmetric crural oedemas. Physical exami-
nation showed discreet crepitations on the base of
the lungs, regular heart rhythm 110/min, blood
pressure 100/80 mmHg, mild crural oedemas.
Anomalous results of laboratory tests were as follows:
normocytic anemia: red blood cells 3.28 mln/mm3
(normal values: 3.50–5.50 mln/mm3), hemoglobin
9.9 g/dL (11–18 g/dL), hematocrit 29.3% (35–55%).
Moreover, renal dysfunction features were ob-
served: creatinine level 2.2 mg/dl (0.4–1.5 mg/dL),
urea 92 mg/dL (21–43 mg/dL), without electrolyte
disorders. Electrocardiogram revealed sinus tachy-
cardia 120/min, no arrhythmias, no ischemic fea-
tures. On the third day of hospitalization planned
chemotherapy was initialized and it was continued
as intravenous infusions for four following days:
vincristine 0.4 mg/day, doxorubicin 16 mg/day, dexa-
methasone 40 mg/day. In this period, the patient did
not reveal any new complaints and there was no
progression of renal dysfunction in laboratory tests.
On the second day after chemotherapy, in the ear-
ly morning, the patient reported progressive weak-
ening, dyspnoea and limb shivering. Physical exam-
ination showed tachycardia about 110/min (with
additional premature beats), blood pressure 100/
/60 mm Hg, normal vesicular murmur, without crep-
itations and crural oedemas modestly bigger than
on admission day. About midday, the patient’s clin-
ical state aggravated gradually: dyspnoea increased
rapidly, breathing rate was about 20–30/min,
tachycardia was 120–140/min and hypotension
70/50 mm Hg.
Lungs auscultation revealed a discreet, sym-
metrical decrease in breath sounds, without any
other abnormalities, oxygen saturation about SatO2 =
= 90–96%. In view of a potential cardiac cause of
the sudden worsening of the patient’s state, con-
tinuous monitoring was recommended (electrocar-
diogram, SatO2, blood pressure measurement eve-
ry 30 min). In the meantime troponin I level was
estimated (normal value in two assays). Electrocar-
diogram was also performed (heart rhythm 130/min,
besides as at admission), echocardiography did not
show any features indicating heart failure or
ischemia (normal heart chambers’ diameters, con-
tractility not impaired, ejection fraction 65%). Ox-
ygen and empirical therapy with dopamine at renal
dose and furosemide in continuous infusion (80 mg/
/day initially) was introduced with a moderate im-
provement in blood pressure control (90–100/70–
–80 mm Hg) and without significant clinical amelio-
ration. On the next day, (the tenth day of hospi-
talization) the patient’s general state was still se-
vere: rest dyspnoea, tachypnoe, general weaken-
ing, tachycardia 120–140/min and tendency to hy-
potension persisted; body temperature was 37°C.
Supposing pulmonary thromboembolism, low mo-
lecular weight heparin was introduced at a dose of
1 mg/kg subcutaneously and a computed tomogra-
phy angiography of chest was performed immedi-
ately without presence of embolic material in pul-
monary vessels and any pathology in chest organs.
In laboratory tests, hypoalbuminemia was observed:
total protein level 5.5 g/dL (normal: 6.0–8.0 g/dL),
albumins 2.9 g/dL (3.5–5.5 g/dL), without progres-
sion of renal dysfunction: creatinine level 2.0 mg/dL,
urea level 114 mg/dL, no liver dysfunction. Ongo-
ing treatment was intensified: furosemide in con-
tinuous infusion (80 mg/day), dopamine and dob-
utamine initially at doses 2 μg/kg bw./min and
10 μg/kg bw./min, modified according to blood pres-
sure.
The next day, due to the patient’s persisting
severe general state, significant rest dyspnoea and
weakening, limiting activity to the bed area, imped-
ance cardiography (ICG) was performed (five-
-minute rest examination) with use of Niccomo (Me-
dis, Germany). It revealed a high level of thoracic
fluid content (TFC), low cardiac index (CI), proba-
bly connected with very low stroke index (SI), com-
pensated by a high heart rhythm and systemic vas-
cular resistance. The value of cardioimpedance pa-
rameter describing heart inotropic function,
Heather index (HI), was normal (Table 1). On the
basis of ICG examination, the hypothesis of toxic
lung injury and CLS was propounded. Methyl-
predniosone therapy (Solu-Medrol) at high intrave-
nous doses (initially 1.5 mg/kg bw./day) and a limi-
tation of fluid supply to 2,000 mL/day was intro-
duced. The next day a significant improvement in
the patient’s state was observed, dyspnoea gradual-
ly subsided (SatO2 = 96%, without oxygen therapy),
weakening diminished, breath sounds were normal,
blood pressure 120/80 mm Hg, tachycardia persist-
ed: 130/min. On the third day of methylpredniosone
therapy, in view of our patient’s subsequent ame-
lioration (without dyspnoea, better tolerance of ex-
ercise, discreet crural oedemas), therapy with
dopamine, dobutamine and furosemide was abort-
ed. On the following days of steroid therapy further
improvement in the patient’s general state was
observed. On the sixteenth day of hospitalization,
a control ICG examination was performed and re-
vealed lower heart rhythm (101/min), CI and HI, still
high TFC. On the twentieth day of hospitalization the
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patient was discharged from hospital with recom-
mended oral pharmacotherapy (furosemide 80 mg/
/day, spironolactone 50 mg/day, ramipril 5 mg/day
and prednisone 20 mg with gradual dose reduction).
His next admission to the clinic was planned for one
month hence in order to continue the treatment and
perform control examinations (ICG and echocardio-
graphy).
On admission after one month, the patient was
in a rather good general state, with complaints as
at the first time (general weakening, decreased
exercise tolerance). Physical examination showed
regular heart rhythm 110/min, without other abnor-
malities. In echocardiography examination, hemo-
dynamic function of heart muscle was the same as
during the previous hospitalization. ICG revealed
significant decrease of TFC, normal heart rhythm
(about 75/min), moderately lower CI (Table 1). The
patient underwent a chemotherapy cycle without
anthracyclines (VMCP, vincristine, melphalan, cy-
clophosphamide and prednisone) and no serious
adverse effects were observed in course or after
therapy.
Discussion
Doxorubicin is an antibiotic from the group of
anthracyclines of antineoplastic activity, connect-
ed with its ability to inhibit gene expression and
cause apoptosis of neoplastic cells. The most com-
mon cause of ceasing therapy with doxorubicin is
its cardiotoxicity. Anthracycline-induced cardioto-
xicity can be manifested as acute or subacute (symp-
toms in course of therapy), chronic (in 12 months
after the last dose) and delayed chronic (between
one and five years after therapy). It is character-
ized by impaired heart contractility (ejection frac-
tion < 40–45%) with left ventricle and left atrium
enlargement, rarely with the presence of pericar-
dial fluid. In electrocardiogram, the following can
be observed: sinus tachycardia, prolonged QTc in-
terval, supraventricular and ventricular arrhythmi-
as. Clinically the disease can manifest as acute or
chronic heart failure, arrhythmias or even sudden
cardiac death. It can also be mildly symptomatic or
asymptomatic. The recognized risk factors of an-
thracyclines toxicity are: age (below 4 years and
over 65 years), female sex, previous therapy with
other cytostatic agents (i.e. anthracyclines, cyclo-
phosphamide, fluorouracil), ischemic heart disease,
hypertension, heart valve disease, diabetes melli-
tus, previous or present chest radiotherapy, high
summary dose of drug (> 450–550 mg/m2), espe-
cially in a short time period, and simultaneous ther-
apy with drugs such as cyclophosphamide, mitomy-
cin and paclitaxel [3–5].
In the case we present, among the potential
risk factors of anthracyclines-induced cardiomyop-
athy were: age > 65 years and previous therapy
with doxorubicin (one VAD cycle one month before
admission). On the basis of hemodynamic disregu-
lations (tachycardia, hypotension, arrhythmia in the
shape of supraventricular premature beats) and
severe dyspnoea, on the second day after chemo-
therapy the diagnosis of acute heart failure induced
by anthracyclines was propounded. In the exami-
nations performed (electrocardiography, echocar-
diography, computer tomography angiography, tro-
ponin I test) there was no evidence of heart mus-
cle dysfunction and pulmonary thromboembolism.
Bearing in mind a possible noncardiogenic cause of
dyspnoea, ICG examination was performed. It is
a modern noninvasive tool of hemodynamic monitor-
ing enabling the estimation of cardiac output (CO)
Table 1. Values of hemodynamic parameters in impedance cardiography examinations.
Hemodynamic parameters Impedence cardiography examinations Unit
I II III
10th day 6th day after 52nd day after
of hospitalization examination I examination I
Thoracic fluid content 46.77±0.57 50.93±0.40 30.66±0.18 1/kW
Cardiac index 2.80±0.63 2.09±0.21 1.72±0.33 L/min/m2
Stroke index 21.59±4.91 20.64±2.03 22.75±4.40 mL/m2
Heather index 11.70±2.68 7.08±1.17 7.33±1.24 W/s2
System vascular resistance index 2460.74±433.81 2927.95±306.08 3456.08±524.20 dyn/s/cm5/m2
Heart rhythm 129.53±4.33 101.21±3.28 75.73±2.26 1/min
Systolic blood pressure 120.37±3.50 103.54±2.54 100.92±3.07 mm Hg
Diastolic blood pressure 77.56±1.50 72.79±0.41 70.31±0.73 mm Hg
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and many other hemodynamic parameters such as:
heart rhythm, blood pressure, systemic vascular
resistance and especially thoracic fluid content. It
is used in monitoring patients in intensive care
units, diagnosis and treatment of heart failure and
hypertension [6]. In the case reported, ICG re-
vealed high TFC in presence of very low SI and
normal HI (Table 1). The results of this examina-
tion, performed during the severe clinical state, did
not correspond with the typical hemodynamic pro-
file of acute heart failure. Confrontation of ICG
measurements with physical examination (normal
breath sounds) and echocardiography (normal con-
tractility) proved to be decisive. An analysis of these
results led to the diagnosis of commencing noncar-
diogenic pulmonary interstitial oedema induced by
toxic action of doxorubicin on alveolar-capillary bar-
rier. High thoracic fluid content in presence of low
stroke volume and preserved systolic function of
heart muscle indicated interstitial fluid retention
with decreased preload. Simultaneous progressive
hypoalbuminemia of unknown etiology and increas-
ing crural oedemas confirmed the diagnosis of CLS
with dominating pulmonary manifestation.
It is a rare disease, characterized by sudden
oedemas, hypotension and hypoalbuminemia con-
nected with pathological capillary hyperpermeabil-
ity. On the base of its pathophysiology, there is
endothelial cells damage and activation of local in-
flammatory reaction. The disease is characterized
by multifactor pathogenesis (i.e. bone marrow, liv-
er, renal transplantation, chemotherapy) and var-
ied clinical features (systemic, cutaneous and pul-
monary form). There are reported clinical cases of
CLS in patients with hematopoetic tumors, includ-
ing multiple myeloma [7].
On the basis of available publications present-
ing effective treatment of similar clinical states [8],
in our case methylpredniosone therapy at high in-
travenous doses was introduced with rapid clinical
amelioration. Effectiveness of the therapy con-
firmed toxicin-flammatory pathogenesis of the ob-
served cardio-pulmonary disorders.
Results of the second ICG examination, per-
formed at the time of general state stabilization,
seemed surprising and disappointing at first glance:
TFC persisted high, parameters of cardiac systolic
function (CI, SI, HI) were lower than in the first
examination, significant improvement was limited
to heart rhythm control (Table 1). However, it is
worth mentioning that the first ICG measurement
was performed in a course of treatment with
dopamine and dobutamine that might have affected
the values of contractility parameters. In an analysis
of the cause of fluid retention, persisting hypoalbu-
minemia and prolonged regression of pathophysio-
logical changes in lungs seemed to be important. To
verify this hypothesis, a control ICG examination was
performed after a month, revealing anticipated TFC
normalization (Table 1). In view of the persisting fea-
tures of low cardiac output control, electrocardio-
gram and echocardiography were performed that did
not show any cardiotoxicity of doxorubicin.
Summary
Severe adverse effects connected with chem-
otherapy are a common clinical problem, requiring
urgent and effective treatment. The use of imped-
ance cardiography in the case reported proved im-
portant in the diagnosis of an uncommon syndrome
demanding rapid and specific therapy. The present-
ed case report convinces us that in cases of prob-
lematic and atypical patients, every diagnostic hint
may be of crucial importance in the arduous diag-
nostic-therapeutic process.
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